Neiroserc

Quick links to important sections

Neiroserc

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neiroserc

What is Neiroserc?

Neiroserc is a pharmaceutical preparation containing betahistine dihydrochloride, a synthetic analogue of histamine. It is primarily utilized in the management of vestibular disorders and conditions affecting the inner ear.

Mechanism of Action

The active ingredient in Neiroserc works by interacting with specific histamine receptors located in the inner ear and the central nervous system. Its primary functions include:

  • Improving Microcirculation: It helps to dilate the precapillary sphincters in the inner ear, which increases blood flow to the stria vascularis and vestibular system.
  • Regulating Pressure: By improving circulation, it assists in managing the pressure of the endolymphatic fluid within the ear.
  • Vestibular Compensation: It acts on the central nervous system to facilitate the brain's ability to adapt to balance-related signals.

Primary Uses

Neiroserc is commonly indicated for the treatment of symptoms associated with vestibular dysfunction. These symptoms often include:

  • Vertigo: A sensation of spinning or dizziness often accompanied by nausea.
  • Tinnitus: The perception of ringing or buzzing in the ears without an external source.
  • Hearing Loss: Difficulty hearing that may occur in conjunction with balance issues.

This medication is frequently associated with the symptomatic treatment of Ménière's disease, a chronic disorder characterized by the triad of vertigo, tinnitus, and progressive hearing impairment.

What side effects are possible with Neiroserc?

Possible side effects and safety information

The official safety profile for Betahistine (Neiroserc) is structured by regulatory authorities to classify documented adverse reactions primarily by frequency and the body system affected. These classifications distinguish between frequently reported minor effects and rare, clinically significant events identified through post-marketing surveillance.


Frequency and System-Organ Classes

The most frequently reported effects are classified as Common, affecting up to 1 in 10 patients. These include headache, nausea, and dyspepsia (indigestion), often grouped under Gastrointestinal Disorders and Nervous System Disorders in official labeling.

Adverse events reported spontaneously after the medicine entered the market are classified as Not Known (frequency cannot be estimated). These reactions include hypersensitivity events like anaphylaxis and angioneurotic oedema, as well as other issues such as vomiting, diarrhea, somnolence, and skin reactions (rash, urticaria).


Safety Restrictions and Special Populations

Regulatory documentation defines strict limitations on the use of Betahistine. It is Contraindicated (use is prohibited) in individuals with Phaeochromocytoma (a rare adrenal gland tumor) and a history of peptic ulceration.

Caution is advised for patients with pre-existing conditions such as bronchial asthma or a history of allergic skin conditions. Furthermore, the safety of Betahistine has not been established for use in the pediatric population or during pregnancy, resulting in a regulatory recommendation against its use in these groups.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory sources specify that overdose is primarily characterized by the risk of delayed, progressive liver damage (hepatotoxicity), which can lead to hepatic failure, coma, and death. Symptoms appearing in the first 24 hours often include non-specific signs such as nausea, vomiting, pallor, anorexia, and abdominal pain. It is critical to note that the initial lack of severe symptoms does not correlate with the ultimate risk of irreversible organ damage.

Immediate Action Required

Immediate medical advice must be sought in the event of any suspected overdose, even if the individual feels well. Patients must be urgently referred to a hospital for immediate medical attention.

Overdose Manifestations Serious Outcomes
Nausea, Vomiting, Pallor Hepatic Necrosis and Failure
Abdominal Pain Acute Renal Failure
Symptoms are often mild initially Encephalopathy, Coma, Death

Time-Critical Intervention

The efficacy of the specified antidote, N-acetylcysteine (NAC), is highly time-dependent, offering maximum protective benefit when administered within eight hours of ingestion. Risk factors, including chronic alcohol consumption or malnutrition, may lower the toxic dose threshold required to produce liver injury. Plasma concentrations of the substance must be measured starting four hours post-ingestion to guide treatment protocols.

Therapeutic Uses of Neiroserc

Main Therapeutic Uses

Neiroserc is primarily used to manage symptoms associated with Meniere’s disease and other vestibular disorders. The active ingredient works by improving blood flow in the inner ear and modulating the activity of vestibular neurons, which helps stabilize the sensory signals sent to the brain.

Meniere’s Disease

In the context of Meniere’s disease, the medication is used to address a specific triad of symptoms:

  • Vertigo: Helping to reduce the frequency and intensity of episodes characterized by a spinning sensation or loss of balance.
  • Tinnitus: Assisting in the management of ringing, buzzing, or other phantom noises in the ear.
  • Hearing Loss: Aiding in the stabilization of fluctuating hearing levels often associated with the progression of the condition.

Vestibular Vertigo

Beyond Meniere’s disease, Neiroserc is utilized for the symptomatic treatment of vestibular vertigo. This includes balance disturbances that originate in the inner ear, helping patients regain a sense of equilibrium during daily activities.

Benefits and Expected Outcomes

The primary benefit of treatment is the gradual reduction of disabling balance symptoms. By targeting the underlying pressure and circulatory issues in the inner ear, the medication aims to:

  • Decrease the sudden onset of dizzy spells.
  • Improve overall stability and coordination.
  • Enhance the quality of life for individuals whose daily routines are disrupted by chronic inner ear imbalances.

Effectiveness is typically observed over a period of consistent use, as the physiological adjustments in the inner ear take time to stabilize.

Eligibility and Restrictions for Use

Who Can and Cannot Use Neiroserc?

Eligibility for Neiroserc (Betahistine) use is strictly determined by official regulatory documentation, which outlines specific population contraindications and restrictions.

Contraindications and Restrictions

The medicine is contraindicated and must not be used by patients with Phaeochromocytoma (a rare adrenal gland tumor) or by individuals with known hypersensitivity to the active ingredient or any excipients.

Usage requires caution and monitoring in patients diagnosed with Bronchial Asthma or those with a history of Peptic Ulceration, as these conditions are listed as requiring special consideration.

Population Group Regulatory Status
Children & Adolescents (<18) Not recommended (Insufficient safety/efficacy data)
Pregnant Women Not recommended/Avoid (Inadequate human data)
Breastfeeding Women Not recommended (Excretion into milk unknown)
Adults (18+) Permitted for standard use
Hepatic or Renal Impairment Permitted (No dose adjustment necessary)

The drug is generally approved for use in the adult population, including older adults, with no official requirement for dose adjustment based on post-marketing experience for hepatic or renal impairment.

What should I know about interactions with other medicines?

The official regulatory profile for Neiroserc (Betahistine) documents interactions based primarily on metabolic clearance and pharmacodynamic outcomes. Medicinal product categories with documented interaction potential include Monoamine Oxidase Inhibitors (MAOIs) and H1 Antagonists, which must be used with attention to the labeled constraints.

Metabolic interactions center on the drug's breakdown pathway. In-vitro data indicate that MAO inhibitors, such as the MAO-B selective agent Selegiline, inhibit Betahistine metabolism. This effect could alter Betahistine exposure in the bloodstream, and caution is recommended when these agents are co-administered. Conversely, the official documentation states that no in-vivo inhibition on Cytochrome P450 enzymes is expected.

Pharmacodynamic interactions involve opposing effects at histamine receptors. Concurrent use of H1 Antagonists (antihistamines) may cause a mutual attenuation of effect due to the drug's nature as a histamine analogue. Additionally, potentiation of Betahistine has been reported in a case study involving the beta-agonist Salbutamol.

Regarding consumption constraints, regulatory documents specify that while food slows down the rate of absorption of Betahistine, the total amount absorbed is similar under both fed and fasted conditions. No mandatory timing or separation requirements for administration are noted in the prescribing information. This information strictly reflects the constraints and mechanistic statements found in official government labels.

Mechanism of Action

The action of Neiroserc (Betahistine) is achieved through a dual pharmacological mechanism focused on modulating the body's histaminergic signaling system, resulting in the functional modulation of bilateral vestibular input.


Central Modulation and Vestibular Compensation

The drug's primary effect involves antagonism at the presynaptic Histamine H3 Receptor ( H3 R) within the brainstem . This blockade prevents the H3 R from suppressing the release of endogenous histamine and other neurotransmitters, ultimately facilitating the physiological process of central vestibular compensation.


Peripheral H1 Receptor Activity and Microcirculation

A complementary mechanism involves the drug acting as a weak partial agonist on the Histamine H1 Receptor ( H1 R) located in the microvasculature of the inner ear. This H1 R activity, combined with local H3 R antagonism, promotes localized vasodilation, which influences oxygenation and metabolic supply to the inner ear structures by enhancing local blood flow.


Functional Specificity of the Mechanism

The combined effect of modulating central vestibular neuronal activity and enhancing local perfusion leads to the functional rebalancing of the vestibular pathways. The mechanism is inherently constrained, applying only to the biological processes governed by these specific histamine-mediated vestibular pathways.

Dosage and Administration Information

Neiroserc is a prescription-only medication administered through the oral route, formulated as tablets in strengths of 8 mg, 16 mg, and 24 mg. The standard adult dosage regimen typically begins with an initial dose of 8 mg to 16 mg per dose, usually administered across two or three divided doses throughout the day. The maintenance dose range generally falls between 24 mg and 48 mg daily, with the maximum recommended daily intake limited to 48 mg.

For proper administration, the tablets should be taken preferably with meals or immediately following food consumption. This method is utilized as a strategy to help relieve mild gastric discomfort. If a dose is missed, instructions advise against taking a double dose; the patient should simply continue with the next scheduled dose at the usual time.

Regarding special populations, the medication is not recommended for use in children or adolescents under the age of 18 due to insufficient data. However, there is no requirement for dose adjustment in older adults or in patients with known renal or hepatic impairment, based on post-marketing experience and the established clinical context. Treatment with Betahistine is typically long-term, and while some individuals notice improvement quickly, optimal clinical results are often observed only after continuous administration over a period of several weeks or even months. The 16 mg tablets are scored for dose division, but the score lines on the 24 mg tablets are present solely to aid swallowing, not to create equal halves for dosing.

Recent Clinical Evidence

Neiroserc: Recent Clinical Evidence


Evidence for Use in Ménière's Disease

Research has explored studies of Neiroserc that examined Ménière's disease, a condition characterized by fluctuating symptoms. Studies primarily included Randomized Controlled Trials (RCTs) and Systematic Reviews that monitored the frequency, duration, and severity of vertigo attacks, alongside tinnitus and hearing function. The evidence helps contextualize symptom patterns, but scientific reviews report the overall certainty remains low to very low. Findings were mixed; some high-quality trials reported that measurements of attack frequency were similar between Neiroserc and placebo.


Evidence for Use in General Vestibular Vertigo

Research has explored studies examining patients with the broader range of peripheral vestibular vertigo symptoms. This evidence base includes analyses that pool data from older RCTs and observational studies which focused on monitoring overall change in vertigo symptoms over defined time intervals. The evidence is characterized by a high degree of variability (heterogeneity) in the patient populations studied, and the overall evidence quality for this general population remains low.


Long-Term Research and Evidence in Specific Populations

The majority of available trials provide evidence over short-term periods (three months or less), meaning long-term effects are not fully established and follow-up durations were limited. Furthermore, research primarily focused on adults and provides very limited information regarding use in children (pediatric populations) or patients with specific comorbid conditions.


Evidence Quality, Inconsistencies, and Research Gaps

The evidence base describes areas of ongoing uncertainty. The overall evidence quality varies across studies, with systematic reviews noting that sample sizes were modest and methodological limitations were present. The research available does not conclusively separate the observed changes from the underlying disease’s natural tendency to fluctuate, highlighting what is known and what is still uncertain regarding the full scope of evidence.

Frequently Asked Questions (FAQ)

Common questions about Neiroserc (FAQ)


Q: Is Neiroserc the same as betahistine?

Neiroserc is the brand name used for the active ingredient betahistine. This means that when a patient takes Neiroserc, they are taking the drug betahistine, which is a histamine analogue.

Q: What are the most common side effects of Neiroserc?

According to the official product information, the most frequently reported side effects are classified as Common, affecting up to 1 in 10 patients. These often include headache, nausea, and indigestion (dyspepsia). Patients taking the medication commonly report these effects.

Q: Does Neiroserc affect blood pressure?

Official regulatory documents state that the medicine requires caution and monitoring in patients with severe hypotension (low blood pressure). The medicine is strictly contraindicated (should not be used) in patients with a rare adrenal gland tumor called Phaeochromocytoma, due to the risk of inducing severe high blood pressure.

Q: Is it safe to take Neiroserc with cold and flu medicine?

Neiroserc is a histamine analogue, and concurrent use with certain antihistamines (which are common in cold and flu products) may cause a mutual attenuation, or reduction, of the drug's effect. Official guidelines recommend informing your healthcare professional about all over-the-counter medicines you are taking.

Q: Why do doctors prescribe Neiroserc for ear ringing?

Neiroserc is indicated for the treatment of Ménière's syndrome, which is a condition characterized by a cluster of symptoms. These symptoms include vertigo (dizziness), tinnitus (ear ringing), and hearing loss.

Q: Is Neiroserc a type of sedative or tranquilizer?

No, Neiroserc is classified as an antivertigo agent and a histamine analogue, not a sedative or tranquilizer. However, side effects may include effects such as somnolence (drowsiness) or tiredness. If a patient experiences these effects, they should discuss them with their healthcare professional.

Q: Can Neiroserc be taken long-term?

Yes, treatment with Neiroserc for conditions like Ménière's syndrome is typically considered to be long-term. It may be taken continuously for several months to achieve and maintain optimal clinical results.

Q: Are there any major food interactions with Neiroserc?

According to the official prescribing information, food does not significantly affect the total amount of the drug absorbed. While food may slightly slow down the rate of absorption, the overall amount absorbed remains similar. The medicine is often taken with meals, which may help minimize mild stomach discomfort.

Q: What happens if I forget to take a dose of Neiroserc?

Regulatory instructions advise against taking a double dose to make up for the one that was missed. The recommendation is to simply continue with the next scheduled dose at its usual time.

Q: Does Neiroserc contain any steroids?

No, Neiroserc does not contain any steroids. Its sole active ingredient is Betahistine Dihydrochloride, which is chemically classified as a histamine analogue.

Q: Can Neiroserc cause insomnia or affect sleep?

Official patient information has reported difficulty sleeping (insomnia) as a potential side effect. If sleep disturbances occur, a patient should discuss them with their healthcare professional.

Q: Is there a generic version of Neiroserc available?

Yes, since Neiroserc's active ingredient is betahistine, this drug is widely available as a generic medicine under the name betahistine in many countries where the brand name is used.

Q: Why do some people experience headaches when taking Neiroserc?

Headache is listed in the official safety profile as a Common side effect, meaning it may affect up to 1 in 10 patients who take the medicine. This is a recognized adverse reaction that should be discussed with a healthcare provider if it becomes bothersome.

Q: Does Neiroserc affect kidney or liver function?

Regulatory documents indicate that there is no requirement for dose adjustment in patients with known renal (kidney) or hepatic (liver) impairment. However, increases in liver enzymes have been reported in rare cases.

Q: Is it okay to drive while taking Neiroserc?

The medicine itself is generally considered to have no negative influence on the ability to drive or use machinery. However, since the underlying condition being treated (vertigo or dizziness) can impair driving, patients should exercise caution, especially when starting treatment.

Q: What's the main function of the active ingredient in Neiroserc?

The main function of betahistine is as a histamine analogue that acts on receptors in the brain and inner ear. This mechanism is designed to help modulate histamine levels, stabilize central balance pathways, and promote improved localized blood flow (microcirculation) in the inner ear.

Q: How quickly does Neiroserc start to work for dizziness?

While some people may start to feel initial effects quickly, studies and official information show that optimal clinical results are often observed only after continuous administration over a period of several weeks or even months. Optimal clinical results depend on continuous administration as instructed by a healthcare provider.

Q: Does Neiroserc interact with alcohol?

Official patient information states that consumption of alcohol is generally permitted while taking the medicine. However, alcohol consumption can sometimes worsen symptoms like dizziness or tiredness, which are already associated with the condition being treated.

Q: How long after starting Neiroserc should I expect to see improvement?

Improvement could sometimes be observed after a couple of weeks of treatment, with the best clinical results often obtained after a few months of consistent use. The duration of treatment is determined by the prescribing healthcare provider.

Q: Does Neiroserc help with hearing loss related to Meniere's?

Neiroserc is used for the symptoms of Ménière's syndrome, which includes hearing loss. The regulatory profile notes that using the treatment from the onset of the disease may help prevent the progression of the disease and prevent the loss of hearing in later phases.

Q: Is Neiroserc a maintenance drug or only for acute attacks?

Official information indicates that treatment with Neiroserc is typically long-term. This suggests it is intended to be a maintenance drug for continuous management rather than solely for treating acute attacks.

Q: Why is consistency important when taking Neiroserc?

Consistency in administration is necessary because the best results are often obtained only after continuous use over a period of several months. Following the prescribed regimen is crucial for managing the condition effectively.

Q: What happens if Neiroserc is taken with too much caffeine?

Official patient information notes that patients with Ménière's disease symptoms are often advised to limit caffeine intake as it may worsen their dizziness. Caffeine is a common ingredient in drinks like coffee, tea, and cola.

Q: Is it common for Neiroserc to cause mild indigestion?

Indigestion (dyspepsia) is listed in the official safety profile as a Common side effect, potentially affecting up to 1 in 10 patients. The medicine is often recommended to be taken with meals, which can help to relieve this mild gastric discomfort.

Q: What scientific principle explains how Neiroserc targets the inner ear?

The scientific principle involves influencing the body's histamine receptors. Specifically, the drug targets the Histamine H1-receptors located in the microvasculature of the inner ear, which promotes localized vasodilation (widening of blood vessels) to enhance blood flow and oxygenation.

Q: Is Neiroserc effective for benign paroxysmal positional vertigo (BPPV)?

Official regulatory documents explicitly state that Neiroserc is not the appropriate treatment for Benign Paroxysmal Positional Vertigo (BPPV). Treatment for BPPV typically involves specific physical maneuvers.

How should Neiroserc be stored and disposed of?

Storage Conditions and Requirements

Official regulatory documentation for Neiroserc (betahistine) tablets states that no special storage conditions are required concerning temperature, light, or humidity. The medicine is highly stable and can be stored at typical ambient conditions. It must be kept in its original container to maintain integrity and ensure proper identification.

Storage Aspect Official Requirement
Temperature No special conditions required
Child Safety Must be kept out of the sight and reach of children

Disposal Instructions

Unused or expired Neiroserc should be disposed of in accordance with local requirements for pharmaceutical waste. The official guidance specifies that the medicine must not be disposed of via household wastewater (e.g., flushed down the toilet) or general household trash to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Neiroserc found in:

A-Z Index: